Immunovant, Inc. IMVT Business Segments — Net loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Immunovant, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Immunovant, Inc.’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immunovant, Inc.'s business segments — net loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immunovant, Inc.'s business segments — net loss?
- Immunovant, Inc. (IMVT) reported business segments — net loss of $147.86M in Q1 2026.
- How has Immunovant, Inc.'s business segments — net loss changed year-over-year?
- Immunovant, Inc.'s business segments — net loss increased by 38.9% year-over-year, from $106.45M to $147.86M.
- What is the long-term trend for Immunovant, Inc.'s business segments — net loss?
- Over 3 years (2023 to 2026), Immunovant, Inc.'s business segments — net loss has grown at a 33.8% compound annual growth rate (CAGR), from $210.96M to $505.61M.
- What does business segments — net loss mean?
- The total financial loss generated by the reportable segment after accounting for all operating expenses and non-operating items. For clinical-stage companies, this reflects the burn rate required to fund research and development activities before commercialization. It is a critical metric for evaluating the company's financial sustainability and capital runway.